Science & Enterprise subscription

Follow us on Twitter

  • Wearers of Fitbit activity tracking devices now have the option of sharing their data with a large-scale precision… https://t.co/2tKDCzwGDq
    about 3 hours ago
  • New post on Science and Enterprise: Fitbit Devices Providing Precision Medicine Data https://t.co/6BoD4wI5lI #Science #Business
    about 3 hours ago
  • An alliance of research organizations is designing ways to cut the time needed to develop, test, and manufacture ne… https://t.co/8mnuBqb6q0
    about 7 hours ago
  • New post on Science and Enterprise: Consortium to Speed Vaccine Production https://t.co/uU6E9yjKR9 #Science #Business
    about 7 hours ago
  • New contributed post on Science and Enterprise: https://t.co/iwQvJe2XGc How Your Company Can Make a Positive Impact on the World
    about 10 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Start-Up Licenses Genetics Technology for HIV Diagnostics

David Raiser, left, and Iain MacLeod, founders of Aldatu Biosciences (Aldatu Biosciences)

19 May 2016. A spin-off company from Harvard University is licensing genetics research to develop more powerful tools to detect drug-resistant strains of HIV. Financial details of the agreement between the 2 year-old Aldatu Biosciences Inc. and Harvard were not disclosed.

Aldatu . . . → Read More: Start-Up Licenses Genetics Technology for HIV Diagnostics

Gates Funding RNA Treatment for HIV Infection

RNA molecule illustration (Nicolle Rager Fuller, National Science Foundation)

12 January 2016. The Bill and Melinda Gates Foundation is backing a biotechnology company’s early development of antibodies to treat human immunodeficiency virus or HIV based on RNA, nucleic acids expressed by a person’s genetic code. The foundation is supporting the work of Moderna Therapeutics, . . . → Read More: Gates Funding RNA Treatment for HIV Infection

USC, Biotech Edit Genes in Stem Cells for HIV Therapy

Paula Cannon (University of Southern California)

10 November 2015. A lab at University of Southern California and biotechnology company developed a technique for editing genomes in blood-forming stem cells as a potential treatment for HIV infection. The team from the lab of USC medical school professor Paula Cannon and Sangamo BioSciences in Richmond, California . . . → Read More: USC, Biotech Edit Genes in Stem Cells for HIV Therapy

Research Group, CureVac Partner on AIDS Vaccine

(Rhoda Baer, National Cancer Institute)

10 September 2015. An organization encouraging development of AIDS vaccines and the pharmaceutical company CureVac are collaborating on creating a potent AIDS vaccine technology. Financial and intellectual property aspects of the partnership between the not-for-profit International AIDS Vaccine Initiative, or IAVI, and CureVac in Tubingen, Germany were not disclosed.

. . . → Read More: Research Group, CureVac Partner on AIDS Vaccine

Preventive Drugs Found to Stop New HIV Infections

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

2 September 2015. A large-scale study of preexposure prophylaxis or PrEP, the use of antiviral drugs to prevent HIV infection, found the practice prevented new HIV infections among Kaiser Permanente clients in San Francisco over a 32-month period. Results of the study . . . → Read More: Preventive Drugs Found to Stop New HIV Infections

FDA Approves Pediatric HIV Drug Formulation

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

5 June 2015. The U.S. Food and Drug Administration approved an application for a current HIV drug formulated to better treat infections in infants and young children, especially in limited resource regions. The formulation is a combination of lopinavir and ritonavir in . . . → Read More: FDA Approves Pediatric HIV Drug Formulation

GSK, UNC Chapel Hill Partner on HIV/AIDS Cure

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

11 May 2015. Pharmaceutical maker GlaxoSmithKline and University of North Carolina in Chapel Hill are establishing a joint research center and spin-off company to develop new treatments for HIV and AIDS. GSK says it plans to invest $20 million over 5 years . . . → Read More: GSK, UNC Chapel Hill Partner on HIV/AIDS Cure

Biotech, Universities to Test Hydrogel for Vocal Fold Scars

(A. Kotok)

28 August 2014. BioTime Inc., a biotechnology company in Alameida, California, is partnering with researchers at University of Wisconsin and Université catholique de Louvain in Belgium to test its hydrogels for treating vocal cord scarring, a voice problem that results from injury or disease. Financial terms of the collaboration were not disclosed.

. . . → Read More: Biotech, Universities to Test Hydrogel for Vocal Fold Scars

Early Trial Shows Gene Editing Potential to Treat HIV/AIDS

Bag of altered T-cells for infusion (University of Pennsylvania)

6 March 2014. Researchers from University of Pennsylvania, Albert Einstein College of Medicine, and the biotechnology company Sangamo BioSciences showed the company’s gene-editing technology could engineer the immune cells of HIV-positive patients to resist infection and decrease their viral loads. Results of the early-stage clinical . . . → Read More: Early Trial Shows Gene Editing Potential to Treat HIV/AIDS

Lab-On-Chip Diagnostics Company Lands $2.1M Angel Financing

Prototype cell analyzer (ChipCare Corp.)

ChipCare Corp., a spin-off company from University of Toronto in Canada developing hand-held diagnostics devices to replace fixed expensive lab equipment, secured $2.05 million in early stage angel financing. The deal combines investments from university, private-sector, and Canadian government sources, according to an announcement by Grand Challenges Canada, a . . . → Read More: Lab-On-Chip Diagnostics Company Lands $2.1M Angel Financing